

2026 Specialty Drug List

Specialty medicines treat complex and chronic (long-term) conditions. Examples include multiple sclerosis, hepatitis C, HIV and cancer. Depending on the condition and prescribed therapy, these drugs may be taken by mouth, through a vein, or by injection. Specialty medicines often require specialty handling such as refrigeration. The following specialty medications are covered by WellDyne. This list is not all-inclusive and is subject to change without notice.

AGENTS FOR GAUCHER DISEASE

CERDELGA^{PA, QL}
miglustat^{PA, QL}
yargesa^{PA, QL}

AGENTS FOR PHEOCHROMOCYTOMA

metyrosine^{PA, QL}

ALKYLATING AGENTS

MYLERAN^{PA}

ALPHA-PROTEINASE INHIBITOR (HUMAN)

ARALAST NP^{PA}
GLASSIA^{PA}
PROLASTIN-C^{PA}

AMINO ACIDS

l-glutamine^{PA, QL}

AMINOGLYCOSIDES

ARIKAYCE^{PA, QL}
TOBI PODHALER^{PA, QL}
TOBRAMYCIN^{PA, QL}

AMINOLEVULINATE SYNTHASE 1-DIRECTED SIRNA

GIVLAARI^{PA}

ANDROGEN BIOSYNTHESIS INHIBITORS

abiraterone acetate^{PA, QL}
abirtega^{PA, QL}

ANTI-CATAPLECTIC AGENTS

sodium oxybate^{PA, QL}

ANTI-CATAPLECTIC COMBINATIONS

XYWAV^{PA, QL}

ANTI-IGE MONOCLONAL ANTIBODIES

XOLAIR^{PA}

ANTI-INFECTIVE AGENTS - MISC.

IMPAVIDO^{PA, QL}

ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES

ADALIMUMAB-AATY (1 PEN)^{PA, QL}
ADALIMUMAB-AATY (2 PEN)^{PA, QL}
ADALIMUMAB-AATY (2 SYRINGE)^{PA, QL}

ADALIMUMAB-AATY CD/UC/HS START^{PA, QL}

HADLIMA PUSHTOUCH^{PA, QL}
HADLIMA^{PA, QL}

ANTI-VON WILLEBRAND FACTOR AGENTS

ANTIADRENALS

LYSODREN^{PA, QL}

ANTIANDROGENS

ERLEADA^{PA, QL}
XTANDI^{PA, QL}

ANTIARRHYTHMICS TYPE III

dofetilide

ANTICONVULSANTS - MISC.

DIACOMIT^{PA, QL}
EPIDIOLEX^{PA}
FINTEPLA^{PA, QL}

ANTIDOTES - CHELATING AGENTS

deferasirox granules^{PA}
deferasirox^{PA}
deferiprone^{PA}
FERRIPROX TWICE-A-DAY^{PA, QL}
FERRIPROX^{PA}

ANTIDOTES AND SPECIFIC ANTAGONISTS

ANEXXA
deferoxamine mesylate^{PA}

ANTIHEMOPHILIC PRODUCTS - MONOCLONAL ANTIBODIES

HEMLIBRA^{PA}

ANTIHEMOPHILIC PRODUCTS

ADVATE
ADYNOVATE
AFSTYLA
ALTUVIIIO^{PA}
BENEFIX
ELOCTATE
ESPEROCT
FEIBA
HEMOFIL M
JIVI^{PA}
KOATE
KOVALTRY
NUWIQ
REBINYN
RECOMBINATE
XYNTHA SOLOFUSE
XYNTHA

ANTILEPTOTICS

THALOMID^{PA}

ANTIMETABOLITES

capecitabine^{PA}
INFUGEM
mercaptopurine
TABLOID

ANTIMYCOBACTERIAL AGENTS

SIRTURO^{PA, QL}

ANTINEOPLASTIC - ALK INHIBITORS

ALECENSA^{PA, QL}
ALUNBRIG^{PA, QL}
LORBRENA^{PA, QL}
XALKORI^{PA, QL}
ZYKADIA^{PA, QL}

ANTINEOPLASTIC - ANTI-CD20 ANTIBODIES

RUXIENCE^{PA}

ANTINEOPLASTIC - ANTI-HER2 AGENTS

TUKYSA^{PA, QL}

ANTINEOPLASTIC - BCL-2 INHIBITORS

VENCLEXTA STARTING PACK^{PA, QL}
VENCLEXTA^{PA, QL}

ANTINEOPLASTIC - BCR-ABL KINASE INHIBITORS

BOSULIF^{PA, QL}
dasatinib^{PA, QL}
ICLUSIG^{PA, QL}
imatinib mesylate^{PA, QL}
nilotinib hcl^{PA, QL}
SCEMBLIX^{PA, QL}

ANTINEOPLASTIC - BISPECIFIC T-CELL ENGAGERS

IMDELLTRA^{PA, QL}

ANTINEOPLASTIC - BRAF KINASE INHIBITORS

BRAFTOVI^{PA, QL}
QJEMDA^{PA, QL}
TAFINLAR^{PA, QL}
ZELBORAF^{PA, QL}

ANTINEOPLASTIC - BTK INHIBITORS

BRUKINSA^{PA, QL}
CALQUENCE^{PA, QL}
IMBRUVICA^{PA, QL}
JAYPIRCA^{PA, QL}

ANTINEOPLASTIC - EGFR INHIBITORS

erlotinib hcl^{PA, QL}
gefitinib^{PA, QL}
GILOTRIF^{PA, QL}
TAGRISSO^{PA, QL}
VIZIMPRO^{PA, QL}

ANTINEOPLASTIC - FGFR KINASE INHIBITORS

LYTGOBI (12 MG DAILY DOSE)^{PA, QL}
LYTGOBI (16 MG DAILY DOSE)^{PA, QL}
LYTGOBI (20 MG DAILY DOSE)^{PA, QL}
PEMAZYRE^{PA, QL}
TRUSELTIQ (100MG DAILY DOSE)^{PA, QL}
TRUSELTIQ (125MG DAILY DOSE)^{PA, QL}
TRUSELTIQ (50MG DAILY DOSE)^{PA, QL}
TRUSELTIQ (75MG DAILY DOSE)^{PA, QL}

ANTINEOPLASTIC - GAMMA SECRETASE INHIBITORS

OGSIVEO^{PA, QL}

ANTINEOPLASTIC - HEDGEHOG PATHWAY INHIBITORS

DAURISMO^{PA, QL}
ERIVEDGE^{PA, QL}
ODOMZO^{PA, QL}

ANTINEOPLASTIC - HIF-2-ALPHA INHIBITORS

WELIREG^{PA, QL}

ANTINEOPLASTIC - HISTONE DEACETYLASE INHIBITORS

BELEODAQ
ZOLINZA^{PA, QL}

ANTINEOPLASTIC - IMMUNOMODULATORS

pomalidomide^{PA, QL}

ANTINEOPLASTIC - KRAS INHIBITORS

LUMAKRAS^{PA, QL}

ANTINEOPLASTIC - MEK INHIBITORS

COTELLIC^{PA, QL}
KOSELUGO^{PA, QL}
MEKINIST^{PA, QL}
MEKTOVI^{PA, QL}

ANTINEOPLASTIC - MENIN INHIBITORS

REVUFORJ^{PA, QL}

ANTINEOPLASTIC - MET INHIBITORS

TABRECTA^{PA, QL}
TEPMETKO^{PA, QL}

ANTINEOPLASTIC - METHYLTRANSFERASE INHIBITORS

TAZVERIK^{PA, QL}

ANTINEOPLASTIC - MTOR KINASE INHIBITORS

everolimus^{PA, QL}
torpenz^{PA, QL}

(Continued)

yulithira^{PA, QL}

ANTINEOPLASTIC - MULTIKINASE INHIBITORS

CABOMETYX^{PA, QL}

CAPRELSA^{PA, QL}

COMETRIQ (100 MG DAILY DOSE)^{PA, QL}

COMETRIQ (140 MG DAILY DOSE)^{PA, QL}

COMETRIQ (60 MG DAILY DOSE)^{PA, QL}

FOTIVDA^{PA, QL}

lapatinib ditosylate^{PA, QL}

NERLYNX^{PA, QL}

PAZOPANIB HCL^{PA, QL}

QINLOCK^{PA, QL}

RYDAPT^{PA, QL}

sorafenib tosylate^{PA, QL}

STIVARGA^{PA, QL}

sunitinib malate^{PA, QL}

TURALIO^{PA, QL}

VANFLYTA^{PA, QL}

XOSPATA^{PA, QL}

ANTINEOPLASTIC - PDGFR-ALPHA INHIBITORS

AYYAKIT^{PA, QL}

ANTINEOPLASTIC - PROTEASOME INHIBITORS

NINLARO^{PA, QL}

ANTINEOPLASTIC - RET INHIBITORS

GAVRETO^{PA, QL}

RETEVMO^{PA, QL}

ANTINEOPLASTIC - TROPOMYOSIN RECEPTOR KINASE INHIBITORS

ROZLYTREK^{PA, QL}

VITRAKVI^{PA, QL}

ANTINEOPLASTIC ALKYLATING AGENTS - TOPICAL

VALCHLOR^{PA}

ANTINEOPLASTIC COMBINATIONS

DARZALEX FASPRO^{PA}

INQOVI^{PA, QL}

KISQALI FEMARA (200 MG DOSE)^{PA, QL}

KISQALI FEMARA (400 MG DOSE)^{PA, QL}

KISQALI FEMARA (600 MG DOSE)^{PA, QL}

LONSURF^{PA}

PHESGO^{PA, QL}

ANTINEOPLASTIC RADIOPHARMACEUTICALS

AZEDRA DOSIMETRIC

AZEDRA THERAPEUTIC

ANTINEOPLASTICS MISC.

BESREMI^{PA, QL}

MATULANE^{PA}

NIPENT

SYNRIBO^{PA}

ANTIPSORIATICS - SYSTEMIC

IMULDOSA^{PA, QL}

SKYRIZI PEN^{PA, QL}

SKYRIZI^{PA, QL}

SOTYKTU^{PA, QL}

TALTZ^{PA, QL}

TREMFYA ONE-PRESS^{PA, QL}

TREMFYA PEN^{PA, QL}

TREMFYA^{PA, QL}

YESINTEK^{PA, QL}

ANTIPSYCHOTICS - MISC.

NUPLAZID^{PA, QL}

ANTIRETROVIRAL COMBINATIONS

abacavir sulfate-lamivudine^{QL}

BIKTARVY^{QL}

CABENUVA^{PA, QL}

CIMDUO^{QL}

DESCOVY^{QL}

DOVATO^{QL}

efavirenz-emtricitab-tenofo df^{QL}

EFAVIRENZ-LAMIVUDINE-

TENOFOVIR^{QL}

emtricitabine-tenofovir df^{QL}

GENVOYA^{QL}

JULUCA^{QL}

lamivudine-zidovudine^{QL}

lopinavir-ritonavir^{QL}

ODEFSEY^{QL}

SYM TUZA^{QL}

TRIUMEQ PD^{QL}

TRIUMEQ^{QL}

ANTIRETROVIRALS - CAPSID INHIBITORS

SUNLENCA^{PA, QL}

ANTIRETROVIRALS - CCR5 ANTAGONISTS (ENTRY INHIBITOR)

maraviroc^{QL}

SELZENTRY^{QL}

ANTIRETROVIRALS - FUSION INHIBITORS

FUZEON^{PA, QL}

ANTIRETROVIRALS - GP120-DIRECTED ATTACHMENT INHIBITOR

RUKOBIA^{PA, QL}

ANTIRETROVIRALS - INTEGRASE INHIBITORS

APRETUDE^{PA, QL}

ISENTRESS HD^{QL}

ISENTRESS^{QL}

TIVICAY PD^{QL}

TIVICAY^{QL}

ANTIRETROVIRALS - PROTEASE INHIBITORS

APTIVUS^{QL}

atazanavir sulfate^{QL}

darunavir^{QL}

fosamprenavir calcium^{QL}

NORVIR^{QL}

PREZISTA^{QL}

REYATAZ^{QL}

ritonavir^{QL}

VIRACEPT^{QL}

ANTIRETROVIRALS - RTI-NON-NUCLEOSIDE ANALOGUES

EDURANT PED^{QL}

EFAVIRENZ^{QL}

etravirine^{QL}

INTELENCE^{QL}

NEVIRAPINE ER^{QL}

NEVIRAPINE^{QL}

rilpivirine hcl^{QL}

ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-PURINES

abacavir sulfate^{QL}

ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-PYRIMIDINES

emtricitabine^{QL}

EMTRIVA^{QL}

lamivudine^{QL}

ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-THYMIDINES

STAVUDINE^{QL}

zidovudine^{QL}

ANTIRETROVIRALS - RTI-NUCLEOTIDE ANALOGUES

tenofovir disoproxil fumarate^{QL}

VIREAD^{QL}

ANTIRETROVIRALS ADJUVANTS

TYBOST^{QL}

ANTIRHEUMATIC - JANUS KINASE (JAK) INHIBITORS

RINVOQ LQ^{PA, QL}

RINVOQ^{PA, QL}

ANTIRHEUMATIC ANTIMETABOLITES

RASUVO^{PA, QL}

ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITOR AGENTS

TEGSEDI^{PA, QL}

ANTIVIRAL MONOCLONAL ANTIBODIES

BEYFORTUS^{PA, QL}

SYNAGIS^{PA}

ATOPIC DERMATITIS - JANUS KINASE (JAK) INHIBITORS

ATOPIC DERMATITIS - MONOCLONAL ANTIBODIES

ADBRY^{PA, QL}

B-LYMPHOCYTE STIMULATOR (BLYS)-SPECIFIC INHIBITORS

BENLYSTA^{PA, QL}

BILE ACID SYNTHESIS DISORDER AGENTS

CHOLBAM^{PA}

BISPHOSPHONATES

ibandronate sodium^{PA, QL}

zoledronic acid^{PA, QL}

ZOLEDRONIC ACID^{PA, QL}

BRADYKININ B2 RECEPTOR ANTAGONISTS

icatibant acetate^{PA}

sajazir^{PA}

C1 ESTERASE INHIBITORS

BERINERT^{PA}

CINRYZE^{PA}

HAEGARDA^{PA}

RUCONEST

CALCIMIMETIC AGENTS

cinacalcet hcl^{PA}

CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAG (CGRP)

NURTEC^{PA, QL}

QULIPTA^{PA, QL}

UBRELVIY^{PA, QL}

CARBONIC ANHYDRASE INHIBITORS

dichlorphenamide^{PA, QL}

ormalmiv^{PA, QL}

CARDIAC MYOSIN INHIBITORS

CAMZYOS^{PA, QL}

CFTR POTENTIATORS

KALYDECO^{PA, QL}

CGRP RECEPTOR ANTAGONISTS - MONOCLONAL ANTIBODIES

AIMOVIG^{PA, QL}

AJOVY^{PA, QL}

EMGALITY (300 MG DOSE)^{PA, QL}

EMGALITY^{PA, QL}

CHELATING AGENTS

penicillamine^{PA, QL}

TRIENTINE HCL^{PA, QL}

CHEMOTHERAPY ADJUNCTS - KERATINOCYTE GROWTH FACTORS

KEPIVANCE

CMV AGENTS

LIVTENCITY^{PA, QL}

PREVYMIS^{PA, QL}

(Continued)

COMPLEMENT C3 INHIBITORS EMPAVELI ^{PA, QL}	GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOGS GATTEX ^{PA}	HEPATITIS C AGENTS RIBAVIRIN ^{PA, QL}	INTERLEUKIN-1BETA BLOCKERS ILARIS ^{PA}
COMPLEMENT C5 INHIBITORS SOLIRIS ^{PA} ULTOMIRIS ^{PA, QL}	GLUCOCORTICOSTEROIDS deflazacort ^{PA} jaythari ^{PA} kymbee ^{PA} pyquvi ^{PA} TARPEYO ^{PA, QL}	HEREDITARY OROTIC ACIDURIA TREATMENT - AGENTS XURIDEN ^{PA, QL}	INTERLEUKIN-5 ANTAGONISTS (IGG1 KAPPA) NUCALA ^{PA, QL}
CXCR4 RECEPTOR ANTAGONIST XOLREMDI ^{PA, QL}	GNRH/LHRH ANTAGONISTS cetorelix acetate ^{PA} fyremadel ^{PA} ganirelix acetate ^{PA} ORLISSA ^{PA, QL}	HEREDITARY TYROSINEMIA TYPE 1 (HT-1) TREATMENT - AGENTS nitisinone ^{PA} ORFADIN ^{PA}	INTERLEUKIN-6 RECEPTOR INHIBITORS KEVZARA ^{PA, QL} TYENNE ^{PA, QL}
CYCLIN-DEPENDENT KINASES (CDK) INHIBITORS IBRANCE ^{PA, QL} KISQALI (200 MG DOSE) ^{PA, QL} KISQALI (400 MG DOSE) ^{PA, QL} KISQALI (600 MG DOSE) ^{PA, QL}	GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONISTS FIRMAGON (240 MG DOSE) ^{PA, QL} FIRMAGON ^{PA, QL}	HISTAMINE H3-RECEPTOR ANTAGONIST/INVERSE AGONISTS WAKIX ^{PA, QL}	ISOCITRATE DEHYDROGENASE 1 & 2 (IDH1 & IDH2) INHIBITORS VORANIGO ^{PA, QL}
CYCLOSPORINE ANALOGS LUPKYNIS ^{PA, QL}	GOUT AGENTS KRYSTEXXA ^{PA, QL}	HYDROLYTIC ENZYMES PULMOZYME ^{PA, QL}	ISOCITRATE DEHYDROGENASE-1 (IDH1) INHIBITORS REZLIDHIA ^{PA} TIBSOVO ^{PA, QL}
CYSTIC FIBROSIS AGENT - COMBINATIONS ORKAMBI ^{PA, QL} SYMDEKO ^{PA, QL} TRIKAFTA ^{PA, QL}	GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF) NEULASTA ONPRO ^{PA} NEULASTA ^{PA, QL} NIVESTYM ^{PA} ZARXIO ^{PA} ZIEXTENZO ^{PA}	HYPERAMMONEMIA TREATMENT - AGENTS carglumic acid ^{PA}	ISOCITRATE DEHYDROGENASE-2 (IDH2) INHIBITORS IDHIFA ^{PA, QL}
CYSTINOSIS AGENTS CYSTAGON ^{PA}	GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR(GM-CSF) LEUKINE ^{PA}	HYPOPHOSPHATASIA (HPP) AGENTS STRENSIQ ^{PA}	JANUS ASSOCIATED KINASE (JAK) INHIBITORS INREBIC ^{PA, QL} JAKAFI ^{PA, QL} OJJAARA ^{PA, QL}
ENZYMES XIAFLEX ^{PA}	GROWTH HORMONE RECEPTOR ANTAGONISTS SOMAVERT ^{PA}	ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS BYLVAY (PELLETS) ^{PA, QL} BYLVAY ^{PA, QL}	LEPTIN ANALOGUES MYALEPT ^{PA}
ERYTHROID MATURATION AGENTS REBLOZYL ^{PA}	GROWTH HORMONES GENOTROPIN MINIQUICK ^{PA} GENOTROPIN ^{PA} OMNITROPE ^{PA} SEROSTIM ^{PA} SKYTROFA ^{PA, QL} SOGROYA ^{PA} ZORBITIVE ^{PA}	IMIDAZOTETRAZINES temozolomide ^{PA}	LEVODOPA COMBINATIONS DUOPA
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) PROCRIT ^{PA} RETACRIT ^{PA}	HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITORS OXBRYTA ^{PA, QL}	IMMUNE SERUMS BIVIGAM ^{PA} CUVITRU ^{PA} CYTOGAM FLEBOGAMMA DIF ^{PA} GAMASTAN ^{PA} GAMMAGARD S/D LESS IGA ^{PA} GAMMAGARD ^{PA} GAMMAPLEX ^{PA} GAMUNEX-C ^{PA} HIZENTRA ^{PA} HYPERRHO PANZYGA ^{PA} XEMBIFY ^{PA}	LHRH ANALOGS ELIGARD ^{PA, QL} LEUPROLIDE ACETATE (3 MONTH) ^{QL} leuprolide acetate ^{PA} LUPRON DEPOT (1-MONTH) ^{PA, QL} LUPRON DEPOT (3-MONTH) ^{PA, QL} VABRINTY ^{PA, QL} ZOLADEX ^{PA, QL}
ESTROGENS-ANTINEOPLASTIC EMCYT	HEPATITIS B AGENTS adefovir dipivoxil ^{PA, QL} BARACLUE ^{PA, QL} entecavir ^{PA, QL}	IMMUNOMODULATORS FOR MYELODYSPLASTIC SYNDROMES lenalidomide ^{PA, QL} REVLIMID ^{PA, QL}	LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS LUPRON DEPOT-PED (1-MONTH) ^{PA, QL} LUPRON DEPOT-PED (3-MONTH) ^{PA, QL} SYNAREL ^{PA} TRIPTODUR ^{PA, QL}
FABRY DISEASE - AGENTS GALAFOLD ^{PA, QL}	HEPATITIS C AGENT - COMBINATIONS EPCLUSA ^{PA, QL} HARVONI ^{PA, QL} MAVYRET ^{PA, QL} VOSEVI ^{PA, QL}	INTEGRIN RECEPTOR ANTAGONISTS ENTYVIO PEN ^{PA, QL}	LIPIDS DOJOLVI ^{PA}
FARNESOID X RECEPTOR (FXR) AGONISTS OCALIVA ^{PA, QL}		INTERLEUKIN ANTAGONISTS TREMIFYA-CD/UC INDUCTION ^{PA, QL}	MELANOCORTIN 4 (MC4) RECEPTOR AGONISTS IMCIVREE ^{PA, QL}
FARNESYLTRANSFERASE INHIBITORS ZOKINVY ^{PA, QL}		INTERLEUKIN-1 BLOCKERS ARCALYST ^{PA}	MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS JUXTAPID ^{PA, QL}
GABA MODULATORS vigabatrin ^{PA, QL} vigadron ^{PA, QL} vigpoder ^{PA, QL}			MITOTIC INHIBITORS ETOPOSIDE
GABA RECEPTOR MODULATOR - NEUROACTIVE STEROID ZURZUVAE ^{PA, QL}			

(Continued)

MONOBACTAMS CAYSTON ^{PA, QL}	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH) - AGENTS droxidopa ^{PA, QL}	PALYNZIQ ^{PA} sapropterin dihydrochloride ^{PA} zelvysia ^{PA}	PULM HYPERTEN-SOLUBLE GUANYLATE CYCLASE STIMULATOR (SGC) ADEMPAS ^{PA, QL}
MONOCLONAL ANTIBODIES ENSPRYNG ^{PA, QL}	NITROGEN MUSTARDS AND RELATED ANALOGUES CYCLOPHOSPHAMIDE MELPHALAN ^{PA}	PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS COPIKTRA ^{PA, QL} PIQRAY (200 MG DAILY DOSE) ^{PA, QL} PIQRAY (250 MG DAILY DOSE) ^{PA, QL} PIQRAY (300 MG DAILY DOSE) ^{PA, QL} ZYDELIG ^{PA, QL}	PULMONARY FIBROSIS AGENTS - KINASE INHIBITORS nintedanib esylate ^{PA, QL}
MOVEMENT DISORDER DRUG THERAPY AUSTEDO XR PATIENT TITRATION ^{PA, QL} AUSTEDO XR ^{PA, QL} AUSTEDO ^{PA, QL} INGREZZA ^{PA, QL} tetraabenazine ^{PA, QL}	NITROSOUREAS lomustine ^{PA}	PHOSPHODIESTERASE 4 (PDE4) INHIBITORS OTEZLA XR ^{PA, QL} OTEZLA/OTEZLA XR INITIATION PK ^{PA, QL} OTEZLA ^{PA, QL}	PULMONARY FIBROSIS AGENTS PIRFENIDONE ^{PA, QL}
MS AGENTS - PYRIMIDINE SYNTHESIS INHIBITORS teriflunomide ^{PA, QL}	OPHTHALMIC NERVE GROWTH FACTORS OXERVATE ^{PA, QL}	PLASMA KALLIKREIN INHIBITORS - MONOCLONAL ANTIBODIES TAKHZYRO ^{PA, QL}	PULMONARY HYPERTENSION - ENDOTHELIN RECEPTOR ANTAGONISTS ambrisentan ^{PA, QL} bosentan ^{PA, QL} OPSUMIT ^{PA, QL}
MULTIPLE SCLEROSIS AGENTS - INTERFERONS AVONEX PEN ^{PA, QL} AVONEX PREFILLED ^{PA, QL} BETASERON ^{PA, QL} PLEGRIDY STARTER PACK ^{PA, QL} PLEGRIDY ^{PA, QL} REBIF REBIDOSE TITRATION PACK ^{PA, QL} REBIF REBIDOSE ^{PA, QL} REBIF TITRATION PACK ^{PA, QL} REBIF ^{PA, QL}	OPHTHALMICS - CYSTINOSIS AGENTS CYSTARAN ^{PA, QL}	POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS ORLADEYO ^{PA, QL}	PULMONARY HYPERTENSION - PHOSPHODIESTERASE INHIBITORS alyq ^{PA, QL} sildenafil citrate ^{PA, QL} tadalafil (pah) ^{PA, QL}
MULTIPLE SCLEROSIS AGENTS - MONOCLONAL ANTIBODIES KESIMPTA ^{PA, QL} OCREVUS ^{PA, QL} TYSABRI ^{PA, QL}	OPIOID ANTAGONISTS VIVITROL ^{PA, QL}	POLYMYXINS colistimethate sodium (cba)	RANK LIGAND (RANKL) INHIBITORS PROLIA ^{PA, QL} XGEVA ^{PA, QL}
MULTIPLE SCLEROSIS AGENTS - NRF2 PATHWAY ACTIVATORS dimethyl fumarate starter pack ^{PA, QL} dimethyl fumarate ^{PA, QL}	OPIOID PARTIAL AGONISTS SUBLOCADE ^{PA, QL}	PROGESTERONE RECEPTOR ANTAGONISTS mifepristone ^{PA, QL}	RETINOIC ACID RECEPTOR GAMMA SELECTIVE AGONISTS SOHONOS ^{PA, QL}
MULTIPLE SCLEROSIS AGENTS - POTASSIUM CHANNEL BLOCKERS dalfampridine er ^{PA, QL}	ORNITHINE DECARBOXYLASE (ODC) INHIBITORS IWILFIN ^{PA, QL}	PROGESTINS hydroxyprogesterone caproate ^{PA, QL} MAKENA ^{PA, QL}	ROCK INHIBITORS REZUROCK ^{PA, QL}
MULTIPLE SCLEROSIS AGENTS glatiramer acetate ^{PA, QL} glatopa ^{PA, QL}	OVULATION STIMULANTS-GONADOTROPINS CHORIONIC GONADOTROPIN GONAL-F RFF REDIJECT GONAL-F RFF GONAL-F NOVAREL OVIDREL ^{PA} PREGNYL	PROSTAGLANDIN VASODILATORS epoprostenol sodium ORENITRAM ^{PA, QL} treprostini ^{PA} TYVASO DPI INSTITUTIONAL KIT ^{PA, QL} TYVASO DPI MAINTENANCE KIT ^{PA, QL} TYVASO DPI TITRATION KIT ^{PA, QL} VENTAVIS ^{PA, QL} YUTREPIA ^{PA, QL}	SELECTIVE MELATONIN RECEPTOR AGONISTS tasimelteon ^{PA, QL}
N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTOR ANTAGONISTS SPRAVATO (56 MG DOSE) ^{PA, QL} SPRAVATO (84 MG DOSE) ^{PA, QL}	PARATHYROID HORMONE AND DERIVATIVES TERIPARATIDE ^{PA, QL} TYMLOS ^{PA, QL}	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. MIPLYFFA ^{PA, QL}	SELECTIVE RETINOID X RECEPTOR AGONISTS bexarotene ^{PA}
NATRIURETIC PEPTIDES VOXZOGO ^{PA, QL}	PASSIVE IMMUNIZING AGENTS - COMBINATIONS HYQVIA ^{PA}		SELECTIVE VASOPRESSIN V2-RECEPTOR ANTAGONISTS tolvaptan (hyponatremia) ^{PA, QL} tolvaptan ^{PA, QL}
	PCSK9 INHIBITORS REPATHA PUSHTRONEX SYSTEM ^{PA, QL} REPATHA SURECLICK ^{PA, QL} REPATHA ^{PA, QL}		SMALL INTERFERING RIBONUCLEIC ACID (SIRNA) AGENTS AMVUTTRA ^{PA, QL}
	PDE INHIBITOR-ENDOTHELIN RECEPTOR ANTAGONIST COMBINATIONS OPSYNVI ^{PA, QL}		SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR AGENTS ENBREL MINI ^{PA, QL}
	PHENYLKETONURIA TREATMENT - AGENTS javygtor ^{PA}		

Products covered by a member's prescription benefit plan may change from time to time. Preferred brand products are listed in UPPERCASE LETTERS, generic products are listed in lower-cased italics, and other products listed are non-preferred. Specialty medications are covered based on member's benefit plan design, regardless of their appearance on this document. Additionally, medications listed in this document may require prior authorization.

^{PA} = Prior Authorization Required

ST = Step Therapy Required

^{QL} = Quantity Level Required

ENBREL SURECLICK^{PA, QL}
ENBREL^{PA, QL}

SOMATOSTATIC AGENTS

BYNFEZIA PEN^{PA}
octreotide acetate^{PA}
OCTREOTIDE ACETATE^{PA}
SIGNIFOR^{PA, QL}

SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS (GI)

VELSIPITY^{PA, QL}

SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS

fingolimod hcl^{PA, QL}
ZEPOSIA 7-DAY STARTER PACK^{PA, QL}
ZEPOSIA STARTER KIT^{PA, QL}
ZEPOSIA^{PA, QL}

SPINAL MUSCULAR ATROPHY-SMN2 SPLICING MODIFIERS

EVRYSDI^{PA, QL}

THROMBOPOIETIN (TPO) RECEPTOR AGONISTS

DOPTELET SPRINKLE^{PA, QL}
DOPTELET^{PA, QL}
eltrombopag olamine^{PA, QL}
NPLATE^{PA}

TOPOISOMERASE I INHIBITORS

HYCAMTIN^{PA}

TRANSTHYRETIN STABILIZERS

ATTRUBY^{PA, QL}
VYNDAMAX^{PA, QL}
VYNDAQEL^{PA, QL}

TRYPTOPHAN HYDROXYLASE INHIBITORS

XERMELO^{PA, QL}

TUMOR NECROSIS FACTOR ALPHA BLOCKERS

CIMZIA (1 SYRINGE)^{PA, QL}
CIMZIA (2 SYRINGE)^{PA, QL}
CIMZIA-STARTER^{PA, QL}
CIMZIA^{PA, QL}
INFLECTRA^{PA}
ZYMFENTRA (1 PEN)^{PA, QL}
ZYMFENTRA (2 PEN)^{PA, QL}
ZYMFENTRA (2 SYRINGE)^{PA, QL}

UREA CYCLE DISORDER - AGENTS

glycerol phenylbutyrate^{PA, QL}
sodium phenylbutyrate^{PA}

URINARY STONE AGENTS

tiopronin^{PA}

venxxiva^{PA}

URINARY TRACT PROTECTIVE AGENTS

mesna

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTAGONISTS

BYOOVIZ^{PA}
EYLEA HD^{PA, QL}
EYLEA

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS

ALYMSYS^{PA}
FRUZAQLA^{PA, QL}
INLYTA^{PA, QL}
LENVIMA (10 MG DAILY DOSE)^{PA, QL}
LENVIMA (12 MG DAILY DOSE)^{PA, QL}
LENVIMA (14 MG DAILY DOSE)^{PA, QL}
LENVIMA (18 MG DAILY DOSE)^{PA, QL}
LENVIMA (20 MG DAILY DOSE)^{PA, QL}
LENVIMA (24 MG DAILY DOSE)^{PA, QL}
LENVIMA (4 MG DAILY DOSE)^{PA, QL}
LENVIMA (8 MG DAILY DOSE)^{PA, QL}
MVASI^{PA}
VEGZELMA^{PA}
ZIRABEV^{PA}

VISCOSUPPLEMENTS

EUFLEXXA^{QL}
MONOVISC^{PA, QL}
ORTHOVISC^{PA, QL}

X-LINKED HYPOPHOSPHATEMIA (XLH) TREATMENT - AGENTS

CRYSVITA^{PA, QL}

Products covered by a member's prescription benefit plan may change from time to time. Preferred brand products are listed in UPPERCASE LETTERS, generic products are listed in lower-cased italics, and other products listed are non-preferred. Specialty medications are covered based on member's benefit plan design, regardless of their appearance on this document. Additionally, medications listed in this document may require prior authorization.

^{PA} = Prior Authorization Required

ST = Step Therapy Required

^{QL} = Quantity Level Required